Suggested remit: To appraise the clinical and cost effectiveness of ranibizumab port delivery system within its marketing authorisation for treating wet age-related macular degeneration.
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 3983

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
26 January 2022 - 23 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
26 January 2022 In progress. In progress

For further information on our processes and methods, please see our CHTE processes and methods manual